Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 51

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 51
---
         |                  |     |         |               |       |        |          |       |           |            |     |           |     | 37,500 |                 |     | 1,550,625 |                 |     |      — |               |     |         — |               |
|                                     |     | 1/23/2024 | -8 |     |            |    |     |         |                  |     |         |               |       |        |          |       |           |            |     |           |     |      — |                 |     |         — |                 |     | 10,000 |               |     |   413,500 |               |

(1) All of the option awards were granted under the 2018 Plan, the 2019 Plan or the 2020 Inducement Plan.

(2) All of the stock awards were granted under the 2019 Plan.

(3) The market value of awards in this column is calculated by multiplying the number of shares underlying the award shown in the table by $41.35, the closing price of our common stock on December 31, 2024.

(4) Fully vested.

(5) 1/4th of the shares subject to this option award vest one year after the Grant Date. Thereafter, the shares vest in a series of 36 successive equal monthly installments at the end of each month, provided that the award recipient continues to provide services to us through each such date.

#### Mirum Pharmaceuticals2025 Proxy Statement43

#### TABLE OF CONTENTS

#### Executive Compensation
(6) Represents an RSU award that vests in three equal annual installments on the anniversary of the Grant Date, provided, in each case, that the holder is then providing services to us in accordance with the terms of the 2019 Plan.

(7) Represents the 2023 Executive PSUs, the first tranche of which vested March 15, 2025. As of December 31, 2024, the performance condition of the 2023 Executive PSUs had exceeded the threshold and target performance levels, notwithstanding the fact that the Compensation Committee had not yet certified the achievement of the performance condition. Accordingly, the 2023 Executive PSUs are reported at the maximum performance level.

(8) Represents the 2024 Executive PSUs, which are reported at the target performance level.

#### Option Exercises and Stock Vested
The following table shows for the fiscal year ended December